Cart
sales@molnova.com
L-Ornithine L-aspartate
CAS No. 3230-94-2
L-Ornithine L-aspartate( Ornithine Aspartate )
Catalog No. M27087 CAS No. 3230-94-2
L-Ornithine L-aspartate lowers blood ammonia concentration and to eliminate symptoms of hepatic encephalopathy associated with liver cirrhosis.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | 35 | In Stock |
|
| 500MG | 65 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameL-Ornithine L-aspartate
-
NoteResearch use only, not for human use.
-
Brief DescriptionL-Ornithine L-aspartate lowers blood ammonia concentration and to eliminate symptoms of hepatic encephalopathy associated with liver cirrhosis.
-
DescriptionL-Ornithine L-aspartate lowers blood ammonia concentration and to eliminate symptoms of hepatic encephalopathy associated with liver cirrhosis.
-
In Vitro——
-
In Vivo——
-
SynonymsOrnithine Aspartate
-
PathwayOthers
-
TargetOther Targets
-
RecptorRIP3
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number3230-94-2
-
Formula Weight265.26
-
Molecular FormulaC9H19N3O6
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?H2O : 250 mg/mL (942.47 mM)
-
SMILESN[C@@H](CC(O)=O)C(O)=O.N[C@@H](CCCN)C(O)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Mandal P, et al. RIP3 induces apoptosis independent of pronecrotic kinase activity. Mol Cell. 2014 Nov 20;56(4):481-95.
molnova catalog
related products
-
AS2717638
AS2717638 is an orally active and selective lysophosphatidic acid receptor 5 (LPA5) antagonist (IC50: 38 nM for hLPA5).
-
Compound 35
Compounds 35 are superior inhibitors of Ebola (Mayinga) and Marburg (Angola) infectious viruses.Compounds 35 are superior inhibitors of Ebola (Mayinga) and Marburg (Angola) infectious viruses. Compounds 35 have shown good metabolic stability in plasma and liver microsomes (rat and human), and 32 did not inhibit CYP3A4 nor CYP2C9.
-
CPYPP
CPYPP is an inhibitor of DOCK2-Rac1 interaction. CPYPP binds to DOCK2 DHR-2 domain and inhibits the guanine nucleotide exchange factor (GEF) activity of DOCK2DHR-2 for Rac1 in a dose-dependent manner(IC50 : 22.8 μM).
